Expert Ratings for PTC Therapeutics
Portfolio Pulse from Benzinga Insights
In the last quarter, 19 analysts have provided ratings for PTC Therapeutics (NASDAQ:PTCT), with a majority being indifferent. The company has an average 12-month price target of $47.16, a decrease of 7.38% from the previous average price target of $50.92.
September 19, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
PTC Therapeutics has received mixed ratings from analysts, with a majority being indifferent. The average 12-month price target has decreased, which could potentially impact the stock's performance.
Analyst ratings can significantly influence investor sentiment and stock performance. The decrease in the average 12-month price target suggests that analysts have lowered their expectations for the company, which could lead to a negative impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100